ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstracts tagged "Macrophage"

  • Abstract Number: 1682 • 2015 ACR/ARHP Annual Meeting

    Suppression of Chronic Arthritis By a Novel Nuclear Factor of Activated T-Cell 5 (NFAT5) Inhibitor

    Wan-Uk Kim1, Eun-Jin Han2, Chong-Hyeon Yoon3, Ki-Jo Kim4, Seung-Ah Yoo5, Bong Ki Hong5 and Saseong Lee5, 1Internal Medicine, Seoul St. Mary’s Hospital, The Catholic University of Korea, Seoul, South Korea, 2Institute of Bone & Joint Disease, The Catholic University of Korea, Seoul, South Korea, 3Division of Rheumatology, Department of Internal Medicine, College of Medicine, The Catholic University of Korea, Seoul, South Korea, 4St. Mary's Hospital, Seoul, South Korea, 5Institute of Bone and Joint Diseases, The Catholic University of Korea, Seoul, South Korea

    Background/Purpose: We reported that nuclear factor of activated T-cells 5 (NFAT5), originally identified as an osmo-protective transcription factor, has a critical role in the pathogenesis…
  • Abstract Number: 1767 • 2015 ACR/ARHP Annual Meeting

    Noninvasive Assessment of Macrophage Activation in Experimental Glomerulonephritis Using Optical Imaging with Near-Infrared Light Serves As a Surrogate of Disease Activity

    Sebastian Braehler1, Dongyue Huang2, Matthew Cheung2, Walter Akers3 and Alfred Kim2, 1Pathology & Immunology, Washington University School of Medicine, Saint Louis, MO, 2Rheumatology, Washington University School of Medicine, Saint Louis, MO, 3Mallinckrodt Institute of Radiology, Washington University School of Medicine, Saint Louis, MO

    Background/Purpose: Glomerulonephritis (GN) represents a major cause of morbidity & mortality. The standard for diagnosing GN is through renal biopsy, but this is not performed…
  • Abstract Number: 1778 • 2015 ACR/ARHP Annual Meeting

    Disease Progression Is Altered By Moderate Exercise and Social Stress in a Murine Model of Lupus Nephritis

    Jeffrey Hampton1, Nicholas A. Young2, Sudha Agarwal3, Saba Aqel3, Kendra Jones3, Lai-Chu Wu2,4, Nicole Powell5, John Sheridan5, Michael Bruss3 and Wael N. Jarjour2, 1Immunology and Rheumatoloty, The Ohio State University Wexner Medical Center, Columbus, OH, 2Immunology and Rheumatology, The Ohio State University Wexner Medical Center, Columbus, OH, 3Rheumatology and Immunology, The Ohio State University Wexner Medical Center, Columbus, OH, 4Biological Chemistry and Pharmacology, The Ohio State University College of Medicine, Columbus, OH, 5Institute for Behavioral Medicine Research, The Ohio State University Wexner Medical Center, Columbus, OH

    Background/Purpose:  Chronic inflammation is pathognomonic of autoimmune diseases and contributes to organ damage.  Our group has previously shown that moderate daily exercise reduces systemic inflammation…
  • Abstract Number: 2135 • 2015 ACR/ARHP Annual Meeting

    miRNA-223 Delivery to Synovial Fibroblasts Via Monocyte-Derived Extracellular Vesicles Promotes Their Proliferation

    Florian M.P. Meier1, Derek S. Gilchrist1, Derek Baxter2, Diane Vaughan1, Margaret Mullin3, David W. McCarey4, Pawel Herzyk5, Julie Galbraith5, Donna McIntyre1, Russka Shumnalieva6, Ulf Müller-Ladner7, Iain B. McInnes8 and Mariola Kurowska-Stolarska1, 1Institute of Infection, Immunity and Inflammation, College of Medical, Veterinary and Life Sciences, University of Glasgow, Glasgow, United Kingdom, 2Department of Rheumatology, University Hospital Ayr, Ayr, United Kingdom, 3School of Life Sciences, University of Glasgow, Glasgow, United Kingdom, 4Glasgow Royal Infirmary, Glasgow, United Kingdom, 5Polyomics Facility, Institute of Molecular Cell and Systems Biology, University of Glasgow, Glasgow, United Kingdom, 6Department of Internal Medicine, Clinic of Rheumatology, Sofia, Bulgaria, 7Internal Medicine and Rheumatology, Justus-Liebig-University of Giessen, Kerckhoff-Klinik, Bad Nauheim, Germany, 8Institute of Infection, Immunity and Inflammation, College of Medicine, Veterinary Medicine and Life Sciences, University of Glasgow, Glasgow, United Kingdom

    Background/Purpose: Recently, it was shown that extracellular vesicles (EV) convey microRNAs (miR) from platelets to endothelial cells1and regulate recipient cell gene expression. Interaction of synovial…
  • Abstract Number: 2548 • 2015 ACR/ARHP Annual Meeting

    M-CSF-R Is a Critical Determinant for the Differentiation of Classical to Non-Classical Monocytes

    Philip J. Homan1, Alexander Misharin1, Carla Cuda2, Salina Dominguez2, Rana Saber2, Fu-Nien Tsai3 and Harris R. Perlman4, 1Medicine-Rheumatology, Northwestern University, Chicago, IL, 2Northwestern University, Chicago, IL, 3Medicine, Rhuematology, Northwestern University, Chicago, IL, 4Feinberg School of Medicine, Northwestern University, Chicago, IL

    Background/Purpose: Colony-stimulating factors (CSF) are simply defined as haemotopoitec growth factors. However, CSFs have been implicated to have additional functions in various autoimmune diseases. Specifically…
  • Abstract Number: 2569 • 2015 ACR/ARHP Annual Meeting

    Regulation of SIRT1 Maybe a Perfect Strategy in Treatment of Rheumatoid Arthritis

    Sang-Yeob Lee1, Sung Won Lee2, Won Tae Chung2, Jae Ho Bae3, So Youn Park4 and Chi Dae Kim4, 1Division of Rheumatology, Department of Internal Medicine, Dong-A University College of Medicine, Busan, South Korea, 2Rheumatology, Dong-A University Hospital, Busan, South Korea, 3Biochemistry, Pusan national university, Yong -San, South Korea, 4Medical Research Center for Ischemic Tissue Regeneration, Pusan national university, Yong -San, South Korea

    Background/Purpose: Monocyte may differentiate to osteoclasts in bone and macrophages in joint. so, blocking of monocyte differentiation maybe effective target in RA (rheumatoid arthritis) treatment.…
  • Abstract Number: 2749 • 2015 ACR/ARHP Annual Meeting

    A Phase 1 Study of FPA008, an Anti-Colony Stimulating Factor 1 Receptor (anti-CSF1R) Antibody in Patients (pts) with Rheumatoid Arthritis (RA): Preliminary Results

    Lei Zhou1, Robert Sikorski1, Seema Rogers1, Stefan Costin2, Mariusz Korkosz3, Maria Jaraczewska-Baumann4, Péterfai Éva5, Bernadette Rojkovich6, Janos Bartalos7, Emma Masteller1, Hong Xiang1, Brian Wong1 and Julie Hambleton1, 1Five Prime Therapeutics, Inc., South San Francisco, CA, 2PRA Heath Sciences, Berlin, Germany, 3Malopolskie Centrum Medyczne, The University Hospital in Krakow, Krakow, Poland, 4MedPolonia Sp. z o.o, Poznan, Poland, 5Drug Research Center, Balatonfüred, Hungary, 6Hospitaller Brothers of St. John of God, Budapest, Hungary, 7PRA Hungary Ltd, Budapest, Hungary

    Background/Purpose: FPA008 is a humanized IgG4 anti-CSF1R antibody that blocks the binding of CSF1 and IL34 ligands to CSF1R, resulting in inhibition of the activation…
  • Abstract Number: 3003 • 2014 ACR/ARHP Annual Meeting

    Am80 Ameliorates Bleomycin-Induced Dermal Fibrosis By Suppressing the Pro-Fibrotic Phenotype of Fibroblasts, Endothelial Cells, and Immune Cells

    Tetsuo Toyama1, Yoshihide Asano1, Takehiro Takahashi1, Ryosuke Saigusa1, Yohei Ichimura1, Takashi Taniguchi1, Shinji Noda1, Kaname Akamata1, Shinichi Sato1, Takafumi Kadono1 and Koichi Shudo2, 1Dermatology, University of Tokyo Graduate School of Medicine, Tokyo, Japan, 2Reseach Foundation ITSUU Laboratory, Tokyo, Japan

    Background/Purpose:  Am80 is a synthetic retinoid serving as an agonist for retinoic acid receptor α/β with chemical and pharmacological advantages over all-trans retinoic acid, such…
  • Abstract Number: 2952 • 2014 ACR/ARHP Annual Meeting

    S100A9 Inhibitor Paquinimod (ABR-215757) reduces Joint Destruction in Experimental Osteoarthritis and Blocks Activating Effects of S100A9 in OA Synovium

    Peter L. van Lent1, Rik Schelbergen2, Arjen B. Blom1, Tomas Leanderson3, Helena Eriksson4 and Wim B. van den Berg5, 1Experimental Rheumatology, Radboud university medical center, Nijmegen, Netherlands, 2Radboud university medical center, Nijmegen, Netherlands, 3Immunology Group, Lund University, Lund, Sweden, 4BioScience, Active Biotech AB, Lund, Sweden, 5Experimental Rheumatology (272), Radboud university medical center, Nijmegen, Netherlands

    Background/Purpose Synovial activation is present in more than 50% of osteoarthritis (OA) patients and it is thought to be involved in the development of OA…
  • Abstract Number: 2127 • 2014 ACR/ARHP Annual Meeting

    Subclinical Arthritis Is Detected By Macrophage Targeting and Positron Emission Tomography (PET) in Early RA Patients in Clinical Remission

    Y.Y.J. Gent1, M.M. ter Wee1, D den Uyl1, N. Ahmadi2, W.F. Lems3, O.S. Hoekstra4, A.E. Voskuyl1 and C.J. Van der Laken3, 1Rheumatology, VU University Medical Center, Amsterdam, Netherlands, 2Radiology, VU University Medical Center, Amsterdam, Netherlands, 3Rheumatology, VU Medical Center, Amsterdam, Netherlands, 4Nuclear Medicine, VU Medical Center, Amsterdam, Netherlands

    Background/Purpose: Recurrent flares in RA patients in complete remission (CR) are not an uncommon phenomenon. Studies with advanced imaging techniques have suggested that residual subclinical…
  • Abstract Number: 1714 • 2014 ACR/ARHP Annual Meeting

    IL-6 Trans-Signalling Activates M2 Macrophage Polarisation and Mediates Fibrotic Response in Scleroderma

    Rebecca Alade, Shiwen Xu, Korsa Khan, Angela Tam, Christopher P. Denton and Voon H. Ong, Centre for Rheumatology and Connective Tissue Diseases, UCL Medical School Royal Free Campus, London, United Kingdom

    Background/Purpose IL6 is a key mediator in activation of extracellular matrix (ECM) in scleroderma (SSc) fibroblasts and via its interplay with chemokines may modulate mononuclear…
  • Abstract Number: 1651 • 2014 ACR/ARHP Annual Meeting

    Association of Glomerular Macrophage Phenotypes and Urine Soluble CD163 with Disease Activity in Human Lupus Nephritis

    Naotake Tsuboi1, Nobuhide Endo1, Seiichi Matsuo2 and Shoichi Maruyama1, 1Nephrology, Nagoya University Graduate School of Medicine, Nagoya, Japan, 2Department of Nephrology, Nagoya University Graduate School of Medicine, Nagoya, Japan

    Background/Purpose: In addition to the effector roles of classically activated macrophages for tissue injury, recent studies have shown that alternatively activated (M2) macrophages are involved…
  • Abstract Number: 1486 • 2014 ACR/ARHP Annual Meeting

    Rapid Onset of Clinical Benefit Is Associated with a Reduction in Validated Biomarkers of Disease in Patients with Rheumatoid Arthritis Treated with Mavrilimumab, a Human Monoclonal Antibody Targeting GM-CSFRá

    Iain B. McInnes1, Gerd Burmester2, Joel M. Kremer3, Pedro Miranda4, Mariusz Korkosz5, Jiri Vencovsky6, Andrea Rubbert-Roth7, Eduardo Mysler8, David Close9, Matthew A. Sleeman10, Alex Godwood11, Sara Sandbach12, Patricia C. Ryan13, Dominic Sinibaldi14, Wendy White13, Nadine A. Defranoux15 and Michael Weinblatt16, 1Institute of Infection, Immunity and Inflammation, University of Glasgow, Glasgow, United Kingdom, 2Department of Rheumatology and Clinical Immunology, Charité - University Medicine Berlin, Berlin, Germany, 3Medicine, Albany Medical College and the Center for Rheumatology, Albany, NY, 4Centro de Estudios Reumatologicos, Santiago, Chile, 5Inernal Medicine and Gerontology, Malopolskie Centrum Medyczne, Krakow, Poland, 6Rheumatology, Charles University Institute of Rheumatology, Prague, Czech Republic, 7Med Clinic I, University of Cologne, koln, Germany, 8Rheumatology, OMI, Buenos Aires, Argentina, 9Clinical Development, MedImmune Ltd, Cambridge, United Kingdom, 10Respiratory, Inflammation and Autoimmunity, MedImmune Ltd, Cambridge, United Kingdom, 11Clinical Biostatics and Data Management, MedImmune Ltd, Cambridge, United Kingdom, 12Clinical biologics, MedImmune Ltd, Cambridge, United Kingdom, 13Translational Sciences, MedImmune, Gaithersburg, MD, 14R&D IS Translational & Clinical Informatics, MedImmune, Gaithersburg, MD, 15Crescendo Bioscience Inc., South San Francisco, CA, 16Rheumatology, Brigham & Women's Hospital, Harvard Medical School, Boston, MA

    Background/Purpose Macrophages are pivotal to rheumatoid pathogenesis and their inflammatory products drive many of the signs and symptoms of disease. Mavrilimumab inhibits macrophage activation and…
  • Abstract Number: 1493 • 2014 ACR/ARHP Annual Meeting

    A Phase 1 Study of FPA008, an Anti-Colony Stimulating Factor 1 Receptor (anti-CSF1R) Antibody in Healthy Volunteers and Subjects with Rheumatoid Arthritis (RA): Preliminary Results

    Julie Hambleton1, Lei Zhou1, Seema Rogers1, Sjoerd van Marle2, Thijs van Iersel2, James Zanghi1, Emma Masteller1, Kevin Baker1 and Brian Wong1, 1Five Prime Therapeutics, South San Francisco, CA, 2PRA Health Sciences, Groningen, Netherlands

    Background/Purpose Activation of CSF1R via IL34 or CSF1 results in activation, differentiation, and survival of monocytes, macrophages and osteoclasts.  CSF1R activation produces inflammatory cytokines responsible…
  • Abstract Number: 1209 • 2014 ACR/ARHP Annual Meeting

    Anti-Scavenger Receptor Autoantibodies Disrupted Marginal Zone Macrophage Integrity Via Bruton’s Tyrosine Kinase

    Hao Li1,2, Qi Wu1, PingAr Yang1, Zheng Wang3, Jun Li1, Bao Luo1, Jeffrey C. Edberg1, Hui-Chen Hsu1, John D. Mountz1,4 and Robert P. Kimberly on behalf of PROFILE investigators5, 1Division of Clinical Immunology and Rheumatology, Department of Medicine, University of Alabama at Birmingham, Birmingham, AL, 2Department of Medicine, Clinical Immunology & Rheumatology, University of Alabama at Birmingham, Birmingham, AL, 3Med - Pulmonary/Allergy/Critical Care, University of Alabama at Birmingham, Birmingham, AL, 4Birmingham VA Medical Center, Birmingham, AL, 5Clinical Immun & Rheumatology, Department of Medicine, University of Alabama at Birmingham, Birmingham, AL

    Background/Purpose Ibrutinib, a Btk kinase activity inhibitor, is a novel inhibitor under development for autoimmune disease therapy.  We have shown that Btk was significantly upregulated…
  • « Previous Page
  • 1
  • …
  • 4
  • 5
  • 6
  • 7
  • 8
  • Next Page »
Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology